期刊文献+

BA-ELISA方法检测乳腺癌患者血清p185蛋白 被引量:3

Detection of Seral p185 Protein of Breast Cancer with BA-ELISA
暂未订购
导出
摘要 目的 建立血清p185蛋白新的检测方法,评价血清p185蛋白在乳腺癌诊断中的意义.方法 利用生物素化CerbB-2单克隆抗体,建立血清p185蛋白BA—ELISA检测方法,并对乳腺癌、乳腺增生和正常对照血清进行p185蛋白检测,同时对组织进行p185免疫组化染色。结果 乳腺癌血清p185蛋白与乳腺增生、正常时照相比差异显著(P<0.05),其中免疫组化阳性乳腺癌血清p185蛋白与乳腺增生、正常对照组相比有显著差异(P<0.01),而免疫组化阴性乳腺癌血清p185蛋白与其相比无显著差异(P>0.05);BA-ELISA方法检测血清p185蛋白的敏感度为43.3%,特异度为91.1%,准确度为74.4%、血清p185蛋白水平与乳腺组织p185蛋白表达高度相关(P<0.01).结论 乳腺癌患者血清p185蛋白对乳腺癌具有诊断意义.血清p185蛋白与组织p185蛋白表达高度相关. Objective To establish a new method for seral p185 and investigate clinical significances of seral p185 for breast cancer. Methods Using bio-C-erbB-2 monoclonal antibody, BA-ELISA for seral p185 was established and seral p185 was detected in breast cancer, breast proliferation patients and normal control. The expression of p185 was detected in breast tissues with immunohistochemical assay.Results There are obvious differences comparing breast cancer group with breast proliferation group and normal control group in p185 level(P<(0.05)). In positive p185 staining, there are significant differences comparing the breast carcinoma group with breast proliferation group and normal control group(P<(0.01)). In negative p185 staining, there is no significant differences comparing the breast cancer group with breast proliferation group and normal control group in seral p185 levels(P>(0.05)).The sensitivity,specificity and accuracy of BA-ELISA for seral p185 is (43.3%), (91.1%) and (74.4%) respectively. There is obvious relationship between seral p185 level and tissue's p185 expression(P<(0.01)).Conclusion Seral p185 is of clinical significance in diagnosing breast carcinoma. There is obvious relationship between seral p185 level and tissue's p185 expression in patients with breast carcinoma.
出处 《北华大学学报(自然科学版)》 CAS 2004年第1期27-30,共4页 Journal of Beihua University(Natural Science)
基金 吉林省卫生厅科学基金资助项目(2001)
关键词 乳腺癌 P185蛋白 BA-ELISA Breast carcinoma p185 BA-ELISA
  • 相关文献

参考文献7

  • 1[1]Stenman G, Sandros J, Nordkvist A, et al. Expression of the ERBB-2 Protein in Bengin and Malignant Salivary Gland Tumor[J]. Genes Chromosom Cancer,1991,3(2):128.
  • 2[2]Slamon DJ, Clark GM, Wong SG, et al. Human Breast Cancer: Correlation of Relapse and Survival with the Application of HER-2/neu Oncogene[J]. Science,1987,235:177~182.
  • 3[3]Hynes N E, stem DF. The Biology of ErbB-2/neu/HER-2 and Its Role in Cancer[J]. Biochemica et Biop Hysica Acta,1994,1198:165.
  • 4[4]Ravdin PM, Chamness GC. The c-erbB-2 Proto-oncogene As a Prognostic and Predictive Marker in Breast Caner; A Paradigm for the Development of Other Micromolecmar Marker Review[J]. Gene,1995,159:19.
  • 5[5]Brandt CRauf PW, Luo JC, Carney Wp, et al. Detection of Increased Amounts of the Extracellular Domain of the c-erbB-2 Oncoprotein in Serum during Pulmonary Carcinogenesis in Humans[J]. Int-J-Cancer,1994,156(3):383~386.
  • 6[6]Eitzel K. Elavated Serum c-erbB-2 Antigen Levels and Decreased Response to Hormone Therapy of Breast Cancer[J]. J Clin Oncol,1995,13(5):1129~1135.
  • 7[7]Shigeru I, Hisanao O, Kokichi S, et al. Determination of Cytosol C-erbB2 Protein in Breast Cancer by Sandwich Enzyme Immunoassay[J]. Jpn J Clin,1998,28(2):92.

同被引文献21

  • 1胡勇,饶慧蓉,吴强.癌基因c─erbB─2、抗癌基因p53在乳腺癌中表达的临床病理研究[J].临床与实验病理学杂志,1995,11(1):6-10. 被引量:41
  • 2邵红霞.HER2/neu基因介导的信号传递及其在肿瘤免疫中的作用[J].国外医学(肿瘤学分册),1997,24(1):14-16. 被引量:3
  • 3Kamb A,Gruis NA,Weaver-Feldhaus J,et al.A cell cycle regulator potentially involved in genesis of many tumor types[J].Science,1994,264(5157):436-440.
  • 4Ravdin PM,Chamness GC.The c-erbB-2 proto-oncogene as a prog nostic and predictive marker in breast cancer:a paradigm for the development of other macromolecular markers-a review[J].Gene,1995,159(1):19-27.
  • 5Leitzel K,Teramoto Y,Konrad K,et al.Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer[J].J Clin Oncol,1995,13(5):1129-1135.
  • 6Hynes NE,Stern DF.The biology of erbB-2/neu/HER-2 and its role in cancer[J].Biochim Biophys Acta,1994,1198(2-3):165-184.
  • 7Coussens L,Yang-Feng TL,Liao YC,et al.Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene[J].Science,1985,230(4730):1132-1139.
  • 8Drebin JA,Link VC,Weinberg RA,et al.Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen[J].Proc Natl Acad Sci U S A,1986,83(23):9129-9133.
  • 9Samanta A,LeVea CM,Dougall WC,et al.Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation[J].Proc Natl Acad Sci U S A,1994,91(5):1711-1715.
  • 10Cook DB,Bustamam AA,Brotherick I,et al.Lectin ELISA for the c-erb-B2 tumor marker protein p185 in patients with breast cancer and controls[J].Clin Chem,1999,45(2):292-295.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部